Torsten Hoof Biography and Net Worth

Insider of Exact Sciences

Torsten Hoof has served as our General Manager, International since Exact Sciences’ acquisition of Genomic Health in November 2019. Mr. Hoof joined Genomic Health in September 2017 as Senior Vice President, International and was named Chief Commercial Officer, International in early 2019. Mr. Hoof previously served from 2015 to 2017 as the Vice President and Head of Oncology EMEA at Baxalta, where he built the company's oncology presence in Europe. From 2013 to 2014, Mr. Hoof was also the European General Manager for Endocyte, where he established its European organization designed to bring an innovative, precision medicine solution to patients with ovarian cancer. During his 10 years at Bristol-Myers Squibb, he led the global haemato-oncology franchise and was EMEA General Manager and Vice President for HIV and Primary Care. Earlier in his career with Roche, Torsten led the Tamiflu launch as a Global Business Leader and established Roche's German leadership position in Virology. Torsten also served as an Independent Director at HRA Pharma until its acquisition by Goldman Sachs and Astorg in 2016. Mr. Hoof holds master’s and doctoral degrees from the University of Hannover and is an alumnus of the Boehringer Ingelheim Fonds.

What is Torsten Hoof's net worth?: The estimated net worth of Torsten Hoof is at least $381,229.20 as of September 24th, 2020. Mr. Hoof owns 6,418 shares of Exact Sciences stock worth more than $381,229 as of December 21st. This net worth estimate does not reflect any other investments that Mr. Hoof may own. Learn More about Torsten Hoof's net worth.
How do I contact Torsten Hoof?: The corporate mailing address for Mr. Hoof and other Exact Sciences executives is 5505 ENDEAVOR LANE, MADISON WI, 53719. Exact Sciences can also be reached via phone at (608) 284-5700 and via email at [email protected]. Learn More on Torsten Hoof's contact information.
Has Torsten Hoof been buying or selling shares of Exact Sciences?: Torsten Hoof has not been actively trading shares of Exact Sciences during the last quarter. Most recently, Torsten Hoof sold 4,401 shares of the business's stock in a transaction on Thursday, September 24th. The shares were sold at an average price of $80.00, for a transaction totalling $352,080.00. Following the completion of the sale, the insider now directly owns 6,418 shares of the company's stock, valued at $513,440. Learn More on Torsten Hoof's trading history.
Who are Exact Sciences' active insiders?: Exact Sciences' insider roster includes Brian Baranick (Insider), Sarah Condella (SVP), Kevin Conroy (CEO), D. Coward (Insider), Everett Cunningham (Insider), James Doyle (Director), Jeffrey Elliott (CFO), James Herriott (General Counsel), Torsten Hoof (Insider), Daniel Levangie (Director), Graham Lidgard (Insider), Jacob Orville (Insider), and Katherine Zanotti (Director). Learn More on Exact Sciences' active insiders.
Are insiders buying or selling shares of Exact Sciences?: In the last twelve months, Exact Sciences insiders bought shares 1 times. They purchased a total of 19,500 shares worth more than $1,001,325.00. In the last twelve months, insiders at the medical research company sold shares 35 times. They sold a total of 75,348 shares worth more than $4,597,043.93. The most recent insider tranaction occured on November, 13th when CEO Kevin T Conroy bought 19,500 shares worth more than $1,001,325.00. Insiders at Exact Sciences own 1.4% of the company. Learn More about insider trades at Exact Sciences.
Information on this page was last updated on 11/13/2024.

Torsten Hoof Insider Trading History at Exact Sciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
9/24/2020	Sell	4,401	$80.00	$352,080.00	6,418
8/19/2020	Sell	7,964	$84.90	$676,143.60	9,981

Torsten Hoof Buying and Selling Activity at Exact Sciences

Exact Sciences Company Overview

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

Today's Range

Now: $59.40

$55.98

$59.70

50 Day Range

MA: $61.68

$49.33

$71.93

2 Week Range

Now: $59.40

$40.62

$79.62

Volume

3,273,828 shs

Average Volume

2,615,913 shs

Market Capitalization

$10.99 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.24

Did You See Trump’s Bombshell Exec. Order 001?

From Banyan Hill Publishing | Ad

Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."

I put all the details together for you here — but please hurry.